| Date | Form | Description | Docs | XBRL | Pages |
| 01/30/18 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
14 | |
| 01/30/18 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
14 | |
| 01/26/18 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
36 | |
| 01/23/18 | 8-K | Current report filing |
|
3 | |
| 01/09/18 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
148 |
| 12/12/17 | 8-K | Current report filing |
|
3 | |
| 11/22/17 | 8-K | Current report filing |
|
3 | |
| 11/17/17 | 8-K | Current report filing |
|
3 | |
| 11/17/17 | 8-K | Current report filing |
|
48 | |
| 11/17/17 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
45 |
Latest News & Events
Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024
Read More...Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
Read More...Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
Read More...